8-K: Sangamo Therapeutics Reports Positive Pipeline Progress and Year-End Financial Results

Sangamo Therapeutics announces advancements in its neurology pipeline, key licensing agreements, and financial results for the fourth quarter and full year 2024.

Summary

• Sangamo Therapeutics reported its recent business highlights and financial results for the fourth quarter and full year 2024.
• The company continued to advance its neurology genomic medicine pipeline towards clinical trials.
• Sangamo announced two neurology license agreements with Genentech and Astellas, securing over $100 million in funding through non-dilutive license fees, milestone payments, and equity financing in 2024.
• The FDA cleared the IND application for ST-503 for intractable pain, with patient enrollment expected in mid-2025.
• Nonclinical proof of concept was demonstrated in prion disease, showing reduced prion mRNA and protein expression in mice.
• The FDA aligned on a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec in Fabry disease, potentially accelerating approval by three years.
• Updated Phase 1/2 STAAR study data showed sustained benefit and improvements in kidney function.
• The consolidated net loss for 2024 was $97.9 million, compared to $257.8 million in 2023.
• Revenues for 2024 were $57.8 million, compared to $176.2 million in 2023.
• Cash and cash equivalents as of December 31, 2024, were $41.9 million, expected to fund operations into the middle of the second quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While the company has made significant progress in its pipeline and secured key partnerships, the limited cash runway and need for additional funding raise concerns. The FDA's Accelerated Approval pathway for Fabry disease is a positive sign, but the company's financial stability remains a key factor.

Positives

• Sangamo secured significant licensing agreements with Genentech and Astellas, providing substantial funding.
• The FDA clearance of the IND application for ST-503 allows for clinical trials to begin in mid-2025.
• The alignment with the FDA on a clear regulatory pathway for Fabry disease accelerates the potential approval timeline.
• The Phase 1/2 STAAR study data shows sustained benefits and improvements in kidney function for Fabry disease patients.
• The company is actively engaged in business development negotiations for a potential Fabry commercialization agreement.
• Sangamo is scheduled to regain full rights to giroctocogene fitelparvovec for hemophilia A, allowing them to explore new partnerships.
• Non-GAAP operating expenses are expected to remain stable in 2025, indicating cost management.

Negatives

• Sangamo reported a consolidated net loss of $97.9 million for the year ended December 31, 2024.
• Revenues decreased by $118.4 million in 2024 compared to 2023, primarily due to the termination of collaboration agreements with Biogen and Novartis.
• Cash and cash equivalents as of December 31, 2024, were $41.9 million, expected to fund operations only into the middle of the second quarter of 2025.
• The company needs additional funding to continue operations beyond the middle of the second quarter of 2025.

Risks

• Sangamo's limited cash resources and the need for additional funding pose a significant risk to its ability to continue operations.
• The company's reliance on collaborations and the potential for collaborators to breach or terminate agreements could negatively impact its programs.
• Clinical trial delays, pauses, and holds could affect the timelines and commercialization of product candidates.
• The uncertain and unpredictable nature of clinical trial results and the regulatory approval process could delay or prevent product approvals.
• Macroeconomic factors, financial challenges, and geopolitical instability could impact the business and operations of Sangamo and its collaborators.

Future Outlook

Sangamo expects 2025 operating expenses on a non-GAAP basis to be roughly in line with 2024 and plans to advance isaralgagene civaparvovec towards a potential BLA submission while engaging in business development negotiations for a potential Fabry commercialization agreement.

Management Comments

• 'I am pleased with Sangamo's pipeline progress since the start of 2024,' said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics.
• Macrae also stated that the company has a clear regulatory pathway to Accelerated Approval in Fabry disease, which could reduce the time to potential approval by approximately three years.
• Macrae believes the neurology pipeline represents important potential value.

Industry Context

Sangamo's focus on genomic medicine, particularly in neurology, aligns with the growing trend of gene therapy and gene editing in treating neurological disorders. The licensing agreements with major pharmaceutical companies like Genentech and Astellas highlight the increasing interest in novel delivery technologies like Sangamo's STAC-BBB capsid.

Comparison to Industry Standards

• Sangamo's approach to Fabry disease using gene therapy is comparable to other companies like AVROBIO and Freeline Therapeutics, which are also developing gene therapies for this indication.
• The FDA's Accelerated Approval pathway for isaralgagene civaparvovec is similar to the regulatory strategy used for other gene therapies targeting rare diseases, such as Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy.
• The licensing agreements with Genentech and Astellas are in line with industry trends of pharmaceutical companies collaborating with smaller biotech firms to access innovative technologies and pipelines.

Stakeholder Impact

• Shareholders may be impacted by the need for additional funding, which could potentially dilute existing shares.
• Employees are affected by the company's strategic realignment and cost reductions, including potential workforce reductions.
• Patients with neurological diseases stand to benefit from the advancement of Sangamo's pipeline and potential new treatment options.
• Partners and collaborators are impacted by the company's ability to secure funding and advance its programs.

Next Steps

• Commence patient enrollment and dosing in the clinical study for ST-503 in iSFN in mid-2025.
• Prepare for a potential BLA submission for isaralgagene civaparvovec in Fabry disease in the second half of 2025.
• Continue engaging in business development negotiations for a potential Fabry commercialization agreement.
• Explore how to maximize the value of the SB-525 program, including a search for a potential new collaboration partner.
• Advance CTA enabling activities for Sangamo's product candidate to treat prion disease.
• Participate in the Jefferies Global Healthcare Conference in June 2025 and the Wells Fargo Healthcare Conference in September 2025.

Key Dates